By investing in biotech companies before they became acquisition targets, Todd's HIBEV fund returned more than 30% last year. On Monday, Sanofi and Celgene announced multi-billion dollar biotech acquisitions showing that this investment strategy continues to have legs.
By investing in biotech companies before they became acquisition targets, Todd's HIBEV fund returned more than 30% last year. On Monday, Sanofi and Celgene announced multi-billion dollar biotech acquisitions showing that this investment strategy continues to have legs.
Share this Article
Recommended